NexgenRx Inc.
NEGXF
$0.19
$0.002.55%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.58% | 7.44% | 10.04% | 15.98% | 14.81% |
| Total Other Revenue | 69.62% | 25.15% | 5.15% | 1.69% | 23.27% |
| Total Revenue | 7.08% | 8.15% | 9.84% | 15.40% | 15.11% |
| Cost of Revenue | -11.70% | -2.89% | -0.06% | 0.85% | 14.53% |
| Gross Profit | 12.11% | 11.08% | 12.53% | 19.47% | 15.27% |
| SG&A Expenses | 1.18% | 1.12% | 4.20% | 8.75% | 12.80% |
| Depreciation & Amortization | -3.00% | -4.37% | -5.65% | -4.58% | -5.10% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.97% | -0.21% | 2.40% | 5.80% | 11.43% |
| Operating Income | 294.93% | 632.16% | 873.41% | 924.36% | 2,362.42% |
| Income Before Tax | 536.13% | 43,673.91% | 2,895.67% | 431.81% | 284.42% |
| Income Tax Expenses | 1,482.80% | 1,408.72% | 1,431.25% | 1,417.62% | -84.01% |
| Earnings from Continuing Operations | 443.65% | 4,242.44% | 1,124.09% | 285.90% | 182.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 443.65% | 4,242.44% | 1,124.09% | 285.90% | 182.73% |
| EBIT | 294.93% | 632.16% | 873.41% | 924.36% | 2,362.42% |
| EBITDA | 64.30% | 64.25% | 53.25% | 88.94% | 50.44% |
| EPS Basic | 5,950.00% | 381.48% | 238.71% | 171.43% | 106.06% |
| Normalized Basic EPS | 505.26% | 8,600.00% | 3,550.00% | 435.00% | 258.33% |
| EPS Diluted | 2,725.00% | 302.94% | 194.74% | 161.90% | 89.47% |
| Normalized Diluted EPS | 488.89% | 8,200.00% | 3,450.00% | 447.37% | 263.64% |
| Average Basic Shares Outstanding | 0.13% | 0.31% | 0.45% | 0.59% | 0.68% |
| Average Diluted Shares Outstanding | 5.87% | -0.28% | 0.16% | -2.14% | -2.06% |
| Dividend Per Share | -2.70% | -2.70% | -1.35% | -1.35% | 100.00% |
| Payout Ratio | -0.81% | 1.02% | 1.06% | 1.33% | 3.01% |